In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

Exclusive e-cigarette use is significantly associated with new cases of chronic obstructive pulmonary disease.

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive ...

In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...

Report Ocean’s latest analysis delves into the “Vietnam Pulmonary Arterial Hypertension Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

The PAH Initiative is hosting a video event in May to provide information about exercise benefits for PAH patients.